Company news

Alpha Cognition Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

January 7, 2025

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

January 5, 2025

Alpha Cognition Announces Partial Exercise of Over-allotment Option

December 15, 2024

Alpha Cognition Announces Voluntary Delisting from CSE

December 11, 2024

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

December 10, 2024

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update

November 14, 2024

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks